Novo Nordisk stock holds focus after 2025 growth and 2026 guidance

Novo Nordisk (DK0062498333) remains a closely watched large-cap healthcare name after reporting 2025 sales of DKK 290.4 billion, operating profit of DKK 128.3 billion, and net profit of DKK 101.0 billion. The company also guided for 2026 sales growth of 16% to 24% at constant exchange rates and operating profit growth of 19% to 27%, according to its 2025 annual report and outlook materials.

2025 sales and profit

The 2025 sales base of DKK 290.4 billion was up 26% from DKK 230.2 billion in 2024, while operating profit rose 21% from DKK 106.0 billion to DKK 128.3 billion. Net profit increased 19% from DKK 84.3 billion in 2024 to DKK 101.0 billion in 2025, showing that the profit line expanded more slowly than revenue.

For investors, that combination matters because it gives a concrete benchmark for the next reporting cycle. A 26% revenue increase and a 21% operating-profit increase in the same year also show that Novo Nordisk entered 2026 with scale and still-solid profitability.

2026 guidance range

The companys 2026 outlook points to sales growth of 16% to 24% and operating profit growth of 19% to 27% at constant exchange rates. That implies slower growth than 2025, but the range still leaves room for another year of double-digit expansion if execution holds.

The guidance comparison is the clearest quantified reference point available for the stock narrative. Against 2025s 26% sales growth, the 2026 range signals a moderation rather than a break in the underlying trend.

Margins and cash flow

Operating profit of DKK 128.3 billion on sales of DKK 290.4 billion implies an operating margin of about 44% in 2025. That margin profile is important because it shows Novo Nordisk still converted revenue into earnings at a high rate even as it scaled the top line.

Net profit of DKK 101.0 billion in 2025 also leaves the company with substantial internal funding capacity. That matters for manufacturing, R&D, and product expansion, which remain central to the stock story even when the market is focused on near-term share price swings.

Weight of the portfolio

The leading GLP-1 franchise remains the commercial anchor, but the broader business picture also depends on diabetes care, obesity treatment, and related pipeline execution. Those areas shape whether the 2026 guidance range can be reached or exceeded.

In that sense, the stock narrative is less about a single quarter than about whether Novo Nordisk can sustain the 2025 scale reflected in DKK 290.4 billion of sales. The company entered 2026 with a profit base of DKK 128.3 billion and a guidance range that still implies double-digit growth.

Copenhagen listing

Novo Nordisk stock is listed in Copenhagen, and its latest market context remains tied to that primary venue. When a live quote is available, it belongs beside the report numbers; for now, the durable reference points are the 2025 sales, operating profit, and 2026 outlook already on record.